

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 10-Q**  
(Mark one)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **March 31, 2024**

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-41063

**JOURNEY MEDICAL CORPORATION**  
(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation or organization)

**47-1879539**

(I.R.S. Employer Identification No.)

**9237 E Via de Ventura Blvd, Suite 105, Scottsdale, AZ 85258**  
(Address of principal executive offices and zip code)

**(480) 434-6670**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, par value \$0.0001 per share	DERM	NASDAQ Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	<input type="checkbox"/>	Accelerated Filer	<input type="checkbox"/>
Non-accelerated Filer	<input checked="" type="checkbox"/>	Smaller Reporting Company	<input checked="" type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date.

<b>Class of Common Stock</b>	<b>Outstanding Shares as of May 14, 2024</b>
Common Stock Class A, \$0.0001 par value	6,000,000
Common Stock, \$0.0001 par value	14,012,896

**JOURNEY MEDICAL CORPORATION**  
**Quarterly Report on Form 10-Q**

**TABLE OF CONTENTS**

<b>PART I.</b>	<b><u>FINANCIAL INFORMATION</u></b>	
<u>Item 1.</u>	<u>Condensed Consolidated Financial Statements (unaudited)</u>	1
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	16
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>	22
<u>Item 4.</u>	<u>Controls and Procedures</u>	23
<b>PART II.</b>	<b><u>OTHER INFORMATION</u></b>	
<u>Item 1.</u>	<u>Legal Proceedings</u>	24
<u>Item 1A.</u>	<u>Risk Factors</u>	24
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	24
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>	24
<u>Item 4.</u>	<u>Mine Safety Disclosures</u>	24
<u>Item 5.</u>	<u>Other Information</u>	24
<u>Item 6.</u>	<u>Exhibits</u>	25
<b>SIGNATURES</b>		26

**PART I. FINANCIAL INFORMATION**

**Item 1. Condensed Consolidated Financial Statements (unaudited)**

**JOURNEY MEDICAL CORPORATION**  
**Unaudited Condensed Consolidated Balance Sheets**  
(Dollars in thousands except for share and per share amounts)

	<u>March 31, 2024</u>	<u>December 31, 2023</u>
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	\$ 24,057	\$ 27,439
Accounts receivable, net of reserves	9,799	15,222
Inventory	10,580	10,206
Prepaid expenses and other current assets	2,577	3,588
<b>Total current assets</b>	<u>47,013</u>	<u>56,455</u>
Intangible assets, net	19,473	20,287
Operating lease right-of-use asset, net	79	101
Other assets	6	6
<b>Total assets</b>	<u>\$ 66,571</u>	<u>\$ 76,849</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current liabilities		
Accounts payable	\$ 15,343	\$ 18,149
Due to related party	198	195
Accrued expenses	20,033	20,350
Accrued interest	241	22
Income taxes payable	37	53
Installment payments – licenses, short-term	3,000	3,000
Operating lease liability, short-term	84	99
<b>Total current liabilities</b>	<u>38,936</u>	<u>41,868</u>
Term loan, long-term, net of debt discount	14,684	14,622
Operating lease liability, long-term	—	9
<b>Total liabilities</b>	<u>53,620</u>	<u>56,499</u>
<b>Commitments and contingencies (Note 13)</b>		
<b>Stockholders' equity</b>		
Common stock, \$.0001 par value, 50,000,000 shares authorized, 13,932,310 and 13,323,952 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	1	1
Common stock - Class A, \$.0001 par value, 50,000,000 shares authorized, 6,000,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023	1	1
Additional paid-in capital	95,746	92,703
Accumulated deficit	(82,797)	(72,355)
<b>Total stockholders' equity</b>	<u>12,951</u>	<u>20,350</u>
<b>Total liabilities and stockholders' equity</b>	<u><u>\$ 66,571</u></u>	<u><u>\$ 76,849</u></u>

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

**JOURNEY MEDICAL CORPORATION**  
**Unaudited Condensed Consolidated Statements of Operations**  
(Dollars in thousands except for share and per share amounts)

	Three-Month Periods Ended March 31,	
	2024	2023
<b>Revenue:</b>		
Product revenue, net	\$ 13,030	\$ 12,165
Other revenue	—	48
Total revenue	<u>13,030</u>	<u>12,213</u>
<b>Operating expenses</b>		
Cost of goods sold – product revenue	6,816	6,449
Research and development	7,884	2,033
Selling, general and administrative	<u>8,420</u>	<u>13,292</u>
Total operating expenses	<u>23,120</u>	<u>21,774</u>
Loss from operations	<u>(10,090)</u>	<u>(9,561)</u>
<b>Other expense (income)</b>		
Interest income	(217)	(122)
Interest expense	548	650
Foreign exchange transaction losses	21	47
Total other expense (income)	<u>352</u>	<u>575</u>
<b>Loss before income taxes</b>	<u>(10,442)</u>	<u>(10,136)</u>
Income tax expense		
<b>Net loss</b>	<u><u>\$ (10,442)</u></u>	<u><u>\$ (10,136)</u></u>
Net loss per common share:		
Basic and diluted	\$ (0.53)	\$ (0.57)
Weighted average number of common shares:		
Basic and diluted	19,757,449	17,807,194

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

**JOURNEY MEDICAL CORPORATION**  
**Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity**  
(Dollars in thousands except for share and per share amounts)

**Three-Month Period Ended March 31, 2024**

	Common Stock		Common Stock A		Additional Paid-in Capital	Accumulated Deficit	Total Shareholders' Equity
	Shares	Amount	Shares	Amount			
<b>Balance as of December 31, 2023</b>	<b>13,323,952</b>	<b>\$ 1</b>	<b>6,000,000</b>	<b>\$ 1</b>	<b>\$ 92,703</b>	<b>\$ (72,355)</b>	<b>\$ 20,350</b>
Share-based compensation	—	—	—	—	1,406	—	1,406
Exercise of stock options for cash	55,375	—	—	—	68	—	68
Issuance of common stock for vested restricted stock units	211,028	—	—	—	—	—	—
Issuance of common stock under ESPP	52,211	—	—	—	85	—	85
Issuance of common stock, ATM offering, net of issuance costs of \$46	289,744	—	—	—	1,484	—	1,484
Net loss	—	—	—	—	—	(10,442)	(10,442)
<b>Balance as of March 31, 2024</b>	<b>13,932,310</b>	<b>\$ 1</b>	<b>6,000,000</b>	<b>\$ 1</b>	<b>\$ 95,746</b>	<b>\$ (82,797)</b>	<b>\$ 12,951</b>

**Three-Month Period Ended March 31, 2023**

	Common Stock		Common Stock A		Additional Paid-in Capital	Accumulated Deficit	Total Shareholders' Equity
	Shares	Amount	Shares	Amount			
<b>Balance as of December 31, 2022</b>	<b>11,765,700</b>	<b>\$ 1</b>	<b>6,000,000</b>	<b>\$ 1</b>	<b>\$ 85,482</b>	<b>\$ (68,502)</b>	<b>\$ 16,982</b>
Share-based compensation	—	—	—	—	646	—	646
Issuance of common stock for vested restricted stock units	68,662	—	—	—	—	—	—
Net loss	—	—	—	—	—	(10,136)	(10,136)
<b>Balance as of March 31, 2023</b>	<b>11,834,362</b>	<b>\$ 1</b>	<b>6,000,000</b>	<b>\$ 1</b>	<b>\$ 86,128</b>	<b>\$ (78,638)</b>	<b>\$ 7,492</b>

The accompanying notes are an integral part of these unaudited condensed financial statements

**JOURNEY MEDICAL CORPORATION**  
**Unaudited Condensed Consolidated Statements of Cash Flows**  
(Dollars in thousands except for share and per share amounts)

	Three-Month Periods Ended March 31,	
	2024	2023
<b>Cash flows from operating activities</b>		
Net loss	\$ (10,442)	\$ (10,136)
Adjustments to reconcile net loss to net cash used in operating activities:		
Bad debt expense	6	126
Non-cash interest expense	—	98
Amortization of debt discount	62	17
Amortization of acquired intangible assets	814	1,069
Amortization of operating lease right-of-use assets	22	22
Share-based compensation	1,406	646
Changes in operating assets and liabilities:		
Accounts receivable	5,417	466
Inventory	(374)	881
Prepaid expenses and other current assets	1,011	832
Accounts payable	(2,806)	7,088
Due to related party	3	(43)
Accrued expenses	(317)	(2,013)
Accrued interest	219	5
Income tax payable	(16)	—
Lease liabilities	(24)	(14)
Net cash used in operating activities	<u>(5,019)</u>	<u>(956)</u>
<b>Cash flows from investing activities</b>		
Acquired intangible assets	—	(5,000)
Net cash provided by (used in) investing activities	<u>—</u>	<u>(5,000)</u>
<b>Cash flows from financing activities</b>		
Proceeds from exercise of stock options	68	—
Proceeds from issuance of common stock, ATM offering, net of issuance costs	1,484	—
Issuance of common stock under ESPP	85	—
Proceeds from line of credit	—	28,000
Repayments of line of credit	—	(27,948)
Net cash provided by financing activities	<u>1,637</u>	<u>52</u>
Net change in cash	(3,382)	(5,904)
Cash at the beginning of the period	27,439	32,003
<b>Cash at the end of the period</b>	<b><u>\$ 24,057</u></b>	<b><u>\$ 26,099</u></b>
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	\$ 267	\$ 535
Cash paid for income taxes	\$ —	\$ 7

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

**JOURNEY MEDICAL CORPORATION**  
**Notes to Unaudited Condensed Consolidated Financial Statements**

**NOTE 1. ORGANIZATION AND PLAN OF BUSINESS OPERATIONS**

Journey Medical Corporation ("Journey" or the "Company") is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions. The Company's current product portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the U.S. The Company acquires rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through its field sales organization.

As of March 31, 2024 and December 31, 2023, the Company was a majority-owned subsidiary of Fortress Biotech, Inc. ("Fortress" or "Parent").

***Liquidity and Capital Resources***

At March 31, 2024, the Company had \$ 24.1 million in cash and cash equivalents as compared to \$ 27.4 million of cash and cash equivalents at December 31, 2023.

On December 27, 2023, the Company entered into a Credit Agreement (the "Credit Agreement") with SWK Funding LLC ("SWK"). The Credit Agreement provides for a term loan facility (the "Credit Facility") in the original principal amount of up to \$20.0 million. On the closing date, the Company drew \$15.0 million. The remaining \$5.0 million may be drawn upon the Company's request within 12 months after the closing date. Loans under the Credit Facility (the "Term Loans") mature on December 27, 2027, and bear interest at a rate per annum equal to the three-month term Secured Overnight Financing Rate ("SOFR") (subject to a SOFR floor of 5%) plus 7.75%. The interest rate resets quarterly. Interest payments began in February 2024 and are paid quarterly. Beginning in February 2026, the Company is required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans.

On December 30, 2022, the Company filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission ("SEC") on January 26, 2023. This shelf registration statement covers the offering, issuance and sale by the Company of up to an aggregate of \$150.0 million of the Company's common stock, preferred stock, debt securities, warrants, and units (the "2022 Shelf"). In connection with the 2022 Shelf, the Company entered into an At Market Issuance Sales Agreement (the "Sales Agreement") relating to shares of the Company's common stock. The Company may offer and sell up to 4,900,000 shares of its common stock, from time to time, under the Sales Agreement. During the three months ended March 31, 2024, the Company issued and sold 289,744 shares of common stock under the 2022 Shelf, generating net proceeds of \$ 1.5 million. At March 31, 2024, 3,861,553 shares remain available for issuance under the 2022 Shelf.

The Company regularly evaluates market conditions, its liquidity profile, and financing alternatives, including out-licensing arrangements for its products, to enhance its capital structure. The Company may seek to raise capital through debt or equity financings to expand its product portfolio and for other strategic initiatives, which may include sales of securities under either the 2022 Shelf or a new registration statement or drawing on the SWK Credit Facility. The Company cannot make any assurances that such additional financing will be available and, if available, the terms may negatively impact the Company's business and operations. The Company's expectations are based on current assumptions, projected commercial sales of products, clinical development plans and regulatory submission timelines, which may be uncertain and may not emerge as expected. Additionally, as a result of recurring losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that may be necessary if the Company is unable to continue as a going concern.

## **NOTE 2. BASIS OF PRESENTATION**

### ***Basis of Presentation and Principles of Consolidation***

The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). The Company's consolidated financial statements include the accounts of the Company and the accounts of the Company's wholly-owned subsidiary, JG Pharma, Inc. ("JG" or "JG Pharma"). All intercompany balances and transactions have been eliminated.

### ***Emerging Growth Company***

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company's audited consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended, the Company meets the definition of an emerging growth company and elected the extended transition period for complying with new or revised accounting standards, which delays the adoption of these accounting standards until they would apply to private companies.

### ***Use of Estimates***

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates made by management include provisions for coupons, chargebacks, wholesaler fees, specialty pharmacy discounts, managed care rebates, product returns, and other allowances customary to the pharmaceutical industry. Significant estimates made by management also include inventory realization, valuation of intangible assets, useful lives of amortizable intangible assets and share-based compensation. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company's future results of operations will be affected.

### ***Segment Information***

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions.

## **NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The Company's significant accounting policies are described in Note 2 of the Notes to the Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K").

### ***Accounting Standards Note Yet Adopted***

In November 2023, the FASB issued Accounting Standards Update ("ASU") No. 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which requires that an entity report segment information in accordance with Topic 280, Segment Reporting. The amendment in the ASU is intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments in this update are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on its financial statements and disclosures.

In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which expands disclosures in an entity's income tax rate reconciliation table and disclosures regarding cash taxes paid both in the U.S. and foreign jurisdictions. The update will be effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that this guidance will have on its financial statements and disclosures.

**NOTE 4. INVENTORY**

The Company's inventory consists of the following for the periods ended:

(\$'s in thousands)	March 31, 2024	December 31, 2023
Raw materials	\$ 4,180	\$ 4,640
Work-in-process	805	884
Finished goods	5,865	4,987
Inventory at cost	10,850	10,511
Inventory reserves	(270)	(305)
<b>Total inventories</b>	<b>\$ 10,580</b>	<b>\$ 10,206</b>

**NOTE 5. INTANGIBLE ASSETS**

The Company's finite-lived intangible assets consist of acquired intangible assets. The Company's intangible assets as of March 31, 2024 and December 31, 2023 are summarized as follows:

(\$'s in thousands)	Estimated Useful Lives (Years)	March 31, 2024	December 31, 2023
Intangible assets - product licenses	3-9	\$ 37,925	\$ 37,925
Accumulated amortization		(15,309)	(14,495)
Accumulated impairment loss		(3,143)	(3,143)
<b>Total intangible assets</b>		<b>\$ 19,473</b>	<b>\$ 20,287</b>

The Company's amortization expense for the three-month periods ended March 31, 2024 and 2023 was \$ 0.8 million and \$1.1 million, respectively. Amortization expense is recorded as a component of cost of goods sold in the Company's unaudited condensed consolidated statements of operations.

Future amortization of the Company's intangible assets is as follows:

<i>For the years ended</i>	<i>Total Amortization</i>
Remainder of 2024	\$ 2,443
December 31, 2025	3,257
December 31, 2026	2,471
December 31, 2027	1,775
December 31, 2028	1,595
Thereafter	3,990
<b>Subtotal</b>	<b>15,531</b>
Asset not yet placed in service	3,942
<b>Total</b>	<b>\$ 19,473</b>

**NOTE 6. LICENSES ACQUIRED**

*DFD-29*

In June 2021, the Company entered a license, collaboration, and assignment agreement (the "DFD-29 Agreement") to obtain global rights for the development and commercialization of a late-stage development modified release oral minocycline for the treatment of rosacea ("DFD-29") with Dr. Reddy's Laboratories, Ltd ("DRL"); provided, that DRL retained certain rights to the program in select

## [Table of Contents](#)

markets including Brazil, Russia, India and China. Pursuant to the terms and conditions of the DFD-29 Agreement, the Company paid \$10.0 million. Based on the development and commercialization of DFD-29, additional contingent regulatory and commercial milestone payments totaling up to \$155.0 million may also become payable by the Company. The Company is required to pay royalties ranging from approximately ten percent to twenty percent on net sales of the DFD-29 product, subject to certain reductions. Additionally, the Company was required to fund and oversee the Phase 3 clinical trials beginning after the execution of the DFD-29 Agreement in 2021. The Phase 3 clinical trials substantially concluded in July 2023 upon the Company's receipt of positive Phase 3 clinical trial results.

### *Qbrexza*

In March 2021, the Company executed an Asset Purchase Agreement (the "Qbrexza APA") with Dermira, Inc., a subsidiary of Eli Lilly and Company ("Dermira"). Pursuant to the terms of the Qbrexza APA, the Company acquired the rights to Qbrexza® (glycopyrronium), a prescription cloth towelette to treat primary axillary hyperhidrosis in patients nine years of age or older. The Company paid the upfront fee of \$12.5 million to Dermira. In addition, the Company is obligated to pay Dermira up to \$ 144.0 million in the aggregate upon the achievement of certain sales milestones. The royalty structure for the agreement is tiered with royalties for the first two years ranging from approximately 40% to 30%. Thereafter, royalties are approximately 12.0% to 19.0%. Royalty amounts are subject to certain reductions in the event there is a loss of exclusivity.

### *Accutane*

In July 2020, the Company entered into an exclusive license and supply agreement for Accutane (the "Accutane Agreement") with DRL. Pursuant to the Accutane Agreement, the Company paid \$5.0 million. Three additional milestone payments totaling \$17.0 million are contingent upon the achievement of certain net sales milestones. The Company is required to pay royalties in an amount equal to a low-double digit percentage of net sales. The term of the Accutane Agreement is ten years and renewable upon mutual agreement. Each party may terminate the Accutane Agreement for an uncured material breach by the other party or for certain bankruptcy or insolvency related events. The Company may also terminate the Accutane Agreement without cause upon 180 days written notice to DRL.

### **NOTE 7. FAIR VALUE MEASUREMENTS**

Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

The accounting guidance requires fair value measurements be classified and disclosed in one of the following three categories:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Observable inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3: Unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

Certain of the Company's financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities.

Financial assets and liabilities measured at fair value on a recurring basis are summarized below:

(\$'s in thousands)	March 31, 2024			
	Level 1	Level 2	Level 3	Total
<b>Assets</b>				
Cash and cash equivalents	\$ 24,057	\$ —	\$ —	\$ 24,057
<b>Total</b>	<b>\$ 24,057</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 24,057</b>
 <b>Assets</b>				
	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 27,439	\$ —	\$ —	\$ 27,439
<b>Total</b>	<b>\$ 27,439</b>	<b>\$ —</b>	<b>\$ —</b>	<b>\$ 27,439</b>

The Company did not carry any level 2 or level 3 assets or liabilities at March 31, 2024 or December 31, 2023. No transfers occurred between level 1, level 2, and level 3 instruments during the three-month periods ended March 31, 2024 and 2023.

#### **NOTE 8. RELATED PARTY AGREEMENTS**

##### ***Shared Services Agreement with Fortress***

On November 12, 2021, the Company and Fortress entered into an arrangement to share the cost of certain employees (the "Shared Services Agreement"). Fortress' Executive Chairman and Chief Executive Officer is the Executive Chairman of the Company. Under the terms of the Shared Services Agreement, the Company will reimburse Fortress for the salary and benefit costs associated with these employees based upon actual hours worked on Journey-related projects following the completion of the Company's initial public offering, which occurred in November 2021. In addition, the Company reimburses Fortress for various payroll-related costs and selling, general and administrative costs incurred by Fortress for the benefit of the Company.

For the three-month periods ended March 31, 2024 and 2023, the Company recorded related party expenses to Fortress of approximately \$9,361 and \$15,000, respectively. The due to related party liability at March 31, 2024 and December 31, 2023 was \$ 0.2 million and \$0.2 million, respectively, and primarily relate to reimbursable expenses incurred by Fortress on behalf of the Company. The Company would have incurred these costs irrespective of the relationship with Fortress.

##### ***Fortress Income Tax***

At March 31, 2024, 50.43% of all classes of the Company's outstanding common stock was owned by Fortress. Prior to the Company's initial public offering of securities in 2021, the Company had been filing consolidated federal tax returns and consolidated or combined state tax returns in multiple jurisdictions with Fortress. The Company may still be required to file combined tax returns in certain "combined filing states." These jurisdictions generally require corporations engaged in unitary business and meet the capital stock requirement of fifty percent to file a combined state tax return.

Additionally, see Note 16 below for a discussion of income taxes.

**NOTE 9. ACCRUED EXPENSES**

Accrued expenses consisted of the following:

(\$'s in thousands)	March 31, 2024	December 31, 2023
Accrued expenses:		
Accrued coupons and rebates	\$ 7,169	\$ 9,987
Return reserve	2,806	4,077
Accrued compensation	3,599	3,374
Accrued royalties payable	1,382	2,015
Accrued legal, accounting and tax	335	185
Accrued research and development	3,034	20
Accrued inventory	581	352
Accrued iPledge program	587	174
Other	540	166
<b>Total accrued expenses</b>	<b>\$ 20,033</b>	<b>\$ 20,350</b>

**NOTE 10. OPERATING LEASE OBLIGATIONS**

The Company leases 3,681 square feet of office space in Scottsdale, Arizona. In September 2022, the Company amended the lease to extend the lease term for an additional 25 months at an annual rate of approximately \$0.1 million. The amended lease will expire on January 31, 2025.

The Company recorded lease expense as follows:

(\$'s in thousands)	Three-Month Periods Ended March 31,	
	2024	2023
Operating lease cost	\$ 24	\$ 24
Variable lease cost	1	1
<b>Total lease cost</b>	<b>\$ 25</b>	<b>\$ 25</b>

The following table summarizes quantitative information about the Company's operating leases:

(\$'s in thousands)	Three-Month Periods Ended March 31,	
	2024	2023
Cash paid for amounts included in the measurement of lease liabilities	\$ 25	\$ 17
Weighted-average remaining lease term - operating leases	0.8	1.8
Weighted-average discount rate - operating leases	6.25 %	6.25 %

As of March 31, 2024, future minimum lease payments under lease agreements associated with the Company's operations were as follows:

\$'s in thousands	
Remainder of 2024	\$ 77
2025	9
<b>Total lease payments</b>	<b>86</b>
Less: present value discount	(2)
<b>Total operating lease liabilities</b>	<b>\$ 84</b>

**NOTE 11. DEBT**

The Company's debt obligations at March 31, 2024 and December 31, 2023 were as follows:

(\$'s in thousands)	March 31, 2024	December 31, 2023
Principal balance	\$ 15,000	\$ 15,000
Plus: Exit fee	750	750
Less: Debt discount and fees	\$ (1,066)	\$ (1,128)
<b>Net carry amount (Long-term)</b>	<b>\$ 14,684</b>	<b>\$ 14,622</b>

**SWK Long-Term Debt**

On December 27, 2023 (the "Closing Date"), the Company entered into a Credit Agreement with SWK. The Credit Agreement provides for a term loan Credit Facility in the original principal amount of up to \$20.0 million. On the Closing Date, the Company drew \$15.0 million. The remaining \$5.0 million may be drawn upon request by the Company within 12 months after the Closing Date. Term Loans under the Credit Facility mature on December 27, 2027. The Term Loans accrue interest which is payable quarterly in arrears. The Term Loans bear interest at a rate per annum equal to the three-month term SOFR (subject to a SOFR floor of 5%) plus 7.75%. The interest rate resets quarterly.

Beginning in February 2026, the Company is required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans, with any remaining principal balance due on the maturity date. If the total revenue of the Company, measured on a trailing twelve-month basis, is greater than \$70.0 million as of December 31, 2025, the principal repayment start date is extended from February 2026 to February 2027, at which point the Company is required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 15% of the principal amount of funded Term Loans, with any remaining principal balance due on the maturity date.

The Company may at any time prepay the outstanding principal balance of the Term Loans in whole or in part. Prepayment of the Term Loans is subject to payment of a prepayment premium equal to (i) 2% of the Term Loans prepaid plus the amount of interest that would have been due through the first anniversary of the Closing Date if the Term Loans are prepaid prior to the first anniversary of the Closing Date, (ii) 1% of the Term Loans prepaid if the Term Loans are prepaid on or after the first anniversary of the Closing Date but prior to the second anniversary of the Closing Date, or (iii) 0% if prepaid thereafter.

Upon repayment in full of the Term Loans, the Company will pay an exit fee equal to 5% of the original principal amount of the Term Loans. Additionally, the Company paid an origination fee of \$0.2 million on the Closing Date and incurred issuance costs of \$0.2 million, both of which have been recorded as a debt discount. The Company is accreting the carrying value of the SWK Term Loan to the original principal balance plus the exit fee over the term of the loan using the effective interest method. The amortization of the discount is accounted for as interest expense. The effective interest rate on the SWK Term Loan as of March 31, 2024 was 15.1%. The fair value of the debt approximates its carrying value.

The SWK Credit Facility also includes both revenue and liquidity covenants, restrictions as to payment of dividends, and is secured by substantially all assets of the Company. As of March 31, 2024, the Company was in compliance with the financial covenants under the SWK Credit Facility.

As of March 31, 2024, the contractual maturities of the long-term debt, including the payment of the exit fee, are as follows (dollars in thousands):

<b>Years ending December 31,</b>	<b>Term Loan</b>
Remainder of 2024	\$ —
2025	
2026	4,500
2027	11,250
<b>Total</b>	<b>15,750</b>
Debt discount	(1,066)
<b>Total, net</b>	<b>14,684</b>
Current portion	—
<b>Term-loan (long-term)</b>	<b>\$ 14,684</b>

#### **NOTE 12: INTEREST EXPENSE AND FINANCING FEES**

Interest expense and financing fees for the three months ended March 31, 2024 consisted of the following:

(\$'s in thousands)	Three-Month Periods Ended March 31,	
	2024	2023
Interest payments on term loans and LOC	\$ 486	\$ 535
Amortization/Accretion	62	33
Imputed interest on acquired intangible assets	—	82
<b>Total Interest expense and financing fees</b>	<b>\$ 548</b>	<b>\$ 650</b>

#### **NOTE 13. COMMITMENTS AND CONTINGENCIES**

##### ***License Agreements***

The Company has undertaken to make contingent milestone payments to the licensors of its portfolio of drug products and candidates. In addition, the Company is required to pay royalties to such licensors based on a percentage of net sales of each drug candidate following regulatory marketing approval. For additional information on future milestone payments and royalties, see Note 6.

#### **NOTE 14. SHARE-BASED COMPENSATION**

In 2015, the Company's Board of Directors adopted, and stockholders approved, the Journey Medical 2015 Stock Plan (the "Plan") authorizing the Company to grant shares of common stock to eligible employees, directors, and consultants in the form of restricted stock, restricted stock units ("RSUs"), stock options and other types of grants. The amount, terms, and exercisability provisions of grants are determined by the Board of Directors. The number of shares issuable under the Plan is 7,642,857. As of March 31, 2024, 863,295 shares were available for issuance under the Plan.

The Company, from time to time, grants stock options to employees, non-employees and directors with exercise prices equal to the closing price of the underlying shares of the Company's common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted have a term of ten years from the grant date. Options granted generally vest over four-year period. Compensation cost for stock options is charged against operations on a straight-line basis over the vesting period. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model.

In 2023, the Company's Board of Directors adopted, and stockholders approved, the Journey Medical Corporation 2023 Employee Stock Purchase Plan (the "2023 ESPP"). The Company initially reserved 300,000 shares of common stock for future issuance under the 2023 ESPP. As of March 31, 2024, 247,789 shares were available for issuance under the 2023 ESPP.

[Table of Contents](#)

The following table summarizes the components of share-based compensation expense in the consolidated statements of operations for the three-month period ended March 31, 2024 and 2023:

(\$'s in thousands)	Three-Month Periods Ended March 31,	
	2024	2023
Research and development	\$ 145	\$ 33
Selling, general and administrative	1,261	613
<b>Total non-cash compensation expense related to share-based compensation included in operating expense</b>	<b>\$ 1,406</b>	<b>\$ 646</b>

**Stock Options**

The following table summarizes the Company's stock option activities:

	Number of Shares	Weighted average exercise price	Aggregate intrinsic value	Weighted average remaining contractual life (years)
Outstanding options at December 31, 2023	2,769,869	\$ 1.49	\$ 6,053,833	4.53
Granted	25,000	4.57	—	—
Exercised	(55,375)	1.22	—	—
Forfeited	(65,523)	2.91	—	—
Expired	(1,250)	2.62	—	—
<b>Outstanding options at March 31, 2024</b>	<b>2,672,721</b>	<b>\$ 1.49</b>	<b>\$ 5,866,003</b>	<b>4.23</b>
<b>Options vested and exercisable at March 31, 2024</b>	<b>1,991,507</b>	<b>\$ 0.97</b>	<b>\$ 5,393,973</b>	<b>2.73</b>

For the three-month periods ended March 31, 2024 and 2023, approximately \$ 73,000 and \$0.2 million, respectively, of stock option compensation expense was charged against operations. For the three-month period ended March 31, 2024, the Company issued 55,375 shares of common stock upon the exercise of outstanding stock options and received proceeds \$ 67,514. The Company did not issue any shares of common stock upon the exercise of stock options for the three-month period ended March 31, 2023. At March 31, 2024, the Company had unrecognized stock-based compensation expense related to all unvested options of \$0.8 million, which the Company expects to recognize over a weighted-average period of approximately 1.8 years.

The aggregate intrinsic value in the previous table reflects the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of in-the-money stock options) that would have been received by the option holders had all option holders exercised their options on March 31, 2024. The intrinsic value of the Company's stock options changes based on the closing price of the Company's common stock.

**Restricted Stock Units**

The following table summarizes the activity related to the Company's RSUs for the three-month period ended March 31, 2024:

	Number of units	Weighted average grant date Fair value
Unvested balance at December 31, 2023	1,306,923	\$ 3.88
Granted	887,500	4.97
Vested	(211,028)	3.58
Forfeited	(10,000)	5.02
<b>Unvested balance at March 31, 2024</b>	<b>1,973,395</b>	<b>\$ 4.40</b>

For the three-month periods ended March 31, 2024 and 2023, approximately \$ 1.3 million and \$0.5 million, respectively, of stock compensation expense related to RSUs was charged against operations. For the three-month periods ended March 31, 2024 and 2023

the Company issued 211,028 and 68,662 shares of common stock, respectively, upon vesting of RSU's amounting to \$ 0.8 million and \$0.2 million, respectively, in total aggregate fair market value. At March 31, 2024, 1,973,395 RSUs remained unvested and there was approximately \$4.6 million of unrecognized compensation cost related to restricted stock which the Company expects to recognize over a weighted-average period of approximately 1.6 years.

#### **Employee Stock Purchase Plan**

The 2023 ESPP provides that eligible employees may contribute up to 10% of their eligible earnings toward a semi-annual purchase of the Company's common stock. The 2023 ESPP is qualified under Section 423 of the Internal Revenue Code. The employee's purchase price is derived from a formula based on the closing price of the common stock on the first day of the offering period versus the closing price on the last date of purchase (or, if not a trading day, on the immediately preceding trading day). The offering period under the 2023 ESPP has a duration of six months, and the purchase price with respect to each offering period beginning on or after such date is, until otherwise amended, equal to 85% of the lesser of (i) the fair market value of the Company's common stock at the commencement of the applicable six-month offering period or (ii) the fair market value of the Company's common stock on the purchase date. The Company estimates the fair value of the common stock under the 2023 ESPP using a Black-Scholes valuation model. The fair value was estimated on the date of grant for the offering period beginning February 1, 2024 using the Black-Scholes option valuation model and the straight-line attribution approach with the following assumptions: risk-free interest rate (5.2%); expected term (0.5 years); expected volatility (98%); and an expected dividend yield (0%). The Company recorded \$59,240 of stock-based compensation under the 2023 ESPP for the three-month periods ended March 31, 2024. As of March 31, 2024, there was unrecognized stock-based compensation expense of \$106,110 related to the current ESPP offering period, which ends July 31, 2024.

#### **NOTE 15. REVENUES FROM CONTRACTS WITH CUSTOMERS**

##### ***Disaggregation of Net Revenues***

The Company has the following actively marketed products, Qbrexza®, Amzeeq®, Zilxi®, Accutane®, Exelderm®, Targadox®, and Luxamend®. All of the Company's product revenues are recorded in the U.S.

Revenues by product are summarized as follows:

(\$ in thousands)	Three-Month Periods Ended March 31,	
	2024	2023
Qbrexza®	\$ 5,017	\$ 4,094
Accutane®	5,819	4,648
Amzeeq®	755	1,193
Zilxi®	273	314
Other / legacy	1,166	1,916
<b>Total product revenues</b>	<b>\$ 13,030</b>	<b>\$ 12,165</b>

The Company recognized other revenue as follows:

(\$ in thousands)	Three-Month Periods Ended March 31,	
	2024	2023
Other revenue	—	48
<b>Total other revenue</b>	<b>\$ —</b>	<b>\$ 48</b>

##### ***Significant Customers***

For the three-month periods ended March 31, 2024 and 2023 there were no customers that accounted for more than 10% of the Company's total gross product revenue.

At March 31, 2024, one of the Company's customers accounted for more than 10% of its total accounts receivable balance at 14.0%. At December 31, 2023, one of the Company's customers accounted for more than 10% of its total accounts receivable balance at 13.0%.

**NOTE 16. INCOME TAXES**

(\$ in thousands)	Three-Month Periods Ended March 31,	
	2024	2023
Net Income (loss) before income taxes	\$ (10,442)	\$ (10,136)
Provision (benefit) for Income	—	—
Effective tax rate	0.0 %	0.0 %

The Company records income taxes using the asset and liability method. Deferred income tax assets and liabilities are recognized for the future tax effects attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases, and operating loss and tax credit carryforwards. The Company establishes a valuation allowance if management believes it is more likely than not that the deferred tax assets will not be recovered based on an evaluation of objective verifiable evidence. Management has considered the Company's history of book and tax income and losses incurred since inception, and the other positive and negative evidence, and has concluded that it is more likely than not that the Company will not realize the benefits of the net deferred tax assets as of March 31, 2024.

As of March 31, 2024, the Company had no unrecognized tax benefits and does not anticipate any significant change to the unrecognized tax benefit balance.

**NOTE 17. NET LOSS PER COMMON SHARE**

The Company accounts for and discloses net earnings (loss) per share using the treasury stock method. Net earnings (loss) per share, or basic earnings (loss) per share, is computed by dividing net earnings (loss) by the weighted-average number of shares of common stock outstanding. Net earnings (loss) per share assuming dilutions, or diluted earnings (loss) per share, is computed by reflecting the potential dilution from the exercise of in-the-money stock options and the issuance of non-vested restricted stock units.

The Company's basic and diluted weighted-average number of common shares outstanding for the three-month periods ended March 31, 2024 and 2023 were as follows:

	Three-Month Periods Ended March 31,	
	2024	2023
<b>Basic and diluted</b>		
Potentially dilutive securities:		
Unvested restricted stock units	1,973,395	1,931,969
Stock options	1,624,382	1,130,557
<b>Total potentially dilutive securities</b>	<b>3,597,777</b>	<b>3,062,526</b>

The Company's potentially dilutive securities, including unvested restricted stock and options have been excluded from the computation of diluted loss per share for the three-month periods ended March 31, 2024, and 2023, as the effect would be to reduce the loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted income loss per share is the same for the three-month periods ended March 31, 2024 and 2023.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward-Looking Statements**

*Certain matters discussed in this report may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the "Securities Act"), and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words "anticipate," "believe," "estimate," "may," "expect," "will," "could," "project," "should," "intend" and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in or implied by these forward-looking statements due to a variety of factors, including, without limitation:*

- *the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized;*
- *a substantial portion of our sales derive from products that are without patent protection and/or are or may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income;*
- *we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations;*
- *our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results;*
- *competition could limit our products' commercial opportunity and profitability, including competition from manufacturers of generic versions of our products;*
- *the risk that our products do not achieve broad market acceptance, including by government and third-party payors;*
- *our reliance third parties for several aspects of our operations;*
- *our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful;*
- *the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful development and regulatory approval of the DFD-29 product candidate and any future product candidates that we may develop, in-license or acquire;*
- *clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates;*
- *our competitors could develop and commercialize products similar or identical to ours;*
- *risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products;*
- *our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties' cybersecurity;*
- *the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;*
- *our potential need to raise additional capital;*

- *the substantial doubt expressed about our ability to continue as a going concern;*
- *Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders;*
- *and the risks described in under the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 (the "2023 Form 10-K").*

*The forward-looking statements contained in this report reflect our views and assumptions as of the effective date of this report. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we assume no responsibility for updating any forward-looking statements.*

*We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.*

## **Overview**

We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are actively marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients. We aim to acquire rights to future products by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing, the products through our field sales force.

## **Recent Corporate Highlights**

In July 2023, we announced positive topline data from our two DFD-29 Phase 3 clinical trials for the treatment of papulopustular rosacea. The Phase 3 clinical trials achieved the co-primary and all secondary endpoints, the subjects completed the 16-week treatment and the drug was well-tolerated. DFD-29 demonstrated statistical superiority over both the standard of care, Oracea® capsules, and placebo for Investigator's Global Assessment treatment success and the reduction in the total inflammatory lesion count in both studies. We submitted a New Drug Application ("NDA") under Section 505(b)(2) of the United States Federal Food, Drug and Cosmetic Act ("FDCA") with the U.S. Food and Drug Administration (the "FDA") for DFD-29 on January 4, 2024, paying a \$4.0 million filing fee, and expect potential approval from the FDA in the second half of 2024. On March 18, 2024, we announced the FDA accepted the Company's NDA with a Prescription Drug User Fee Act goal date of November 4, 2024.

## **Critical Accounting Policies and Uses of Estimates**

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

For a discussion of our critical accounting estimates, see the section of the 2023 Form 10-K titled "Management's Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Use of Estimates." There were no material changes in our critical accounting estimates or accounting policies from December 31, 2023.

## **Accounting Pronouncements**

During the three-month period ended March 31, 2024, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2023 Form 10-K that are expected to materially affect the Company's present or future financial statements.

## **Emerging Growth Company and Smaller Reporting Company Status**

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 ("JOBS Act"). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in our annual reports on Form 10-K, an exemption from the requirement to provide an auditor's report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.

We are also a "smaller reporting company," meaning that either (i) the market value of our shares held by non-affiliates is less than \$250 million or (ii) the market value of our shares held by non-affiliates is less than \$700 million and our annual revenue was less than \$100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than \$250 million or (ii) our annual revenue was less than \$100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than \$700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, we have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our consolidated financial statements in this report on Form 10-Q.

## **Results of Operations**

The following table summarizes our results of operations for the three-month periods ended March 31, 2024 and 2023:

**Comparison of the Three-Month Periods Ended March 31, 2024 and 2023**

(\$ in thousands, except per share data)	Three-Month Periods Ended March 31,		Change	
	2024	2023	\$	%
<b>Revenue:</b>				
Product revenue, net	\$ 13,030	\$ 12,165	\$ 865	7 %
Other revenue	—	48	(48)	-100%
<b>Total revenue</b>	<b>13,030</b>	<b>12,213</b>	<b>817</b>	<b>7 %</b>
<b>Operating expenses</b>				
Cost of goods sold – product revenue	6,816	6,449	367	6 %
Research and development	7,884	2,033	5,851	288 %
Selling, general and administrative	8,420	13,292	(4,872)	-37%
<b>Total operating expenses</b>	<b>23,120</b>	<b>21,774</b>	<b>1,346</b>	<b>6 %</b>
Loss from operations	(10,090)	(9,561)	(529)	6 %
<b>Other expense (income)</b>				
Interest income	(217)	(122)	(95)	78 %
Interest expense	548	650	(102)	-16%
Foreign exchange transaction losses	21	47	(26)	-55%
<b>Total other expense (income)</b>	<b>352</b>	<b>575</b>	<b>(223)</b>	<b>-39%</b>
<b>Loss before income taxes</b>	<b>(10,442)</b>	<b>(10,136)</b>	<b>(306)</b>	<b>3 %</b>
Income tax expense	—	—	—	0 %
<b>Net loss</b>	<b>\$ (10,442)</b>	<b>\$ (10,136)</b>	<b>(306)</b>	<b>3 %</b>

**Revenues**

The following table reflects our net product revenue for the three-month periods ended March 31, 2024 and 2023:

(\$ in thousands)	Three-Month Periods Ended		Change	
	2024	2023	\$	%
Qbrexza®	\$ 5,017	\$ 4,094	\$ 923	23 %
Accutane®	5,819	4,648	1,171	25 %
Amzeeq®	755	1,193	(438)	-37%
Zilxi®	273	314	(41)	-13%
Other / legacy	1,166	1,916	(750)	-39%
<b>Total net product revenue</b>	<b>\$ 13,030</b>	<b>\$ 12,165</b>	<b>\$ 865</b>	<b>7 %</b>

Total net product revenues increased by \$0.9 million, or 7%, to \$13.0 million for the three-month period ended March 31, 2024, from \$12.2 million for the three-month period ended March 31, 2023. The increase is primarily due to an increase in net product revenues for Qbrexza and Accutane as we continue to focus our marketing efforts on these products. The increase was partially offset by a decrease in net products revenues from Amzeeq and Zilxi as a result of lower sales volume and Targadox and Ximino. Targadox continues to experience erosion due to generic competition and we discontinued selling Ximino on September 29, 2023.

**Gross-to-Net Sales Accruals**

We record gross-to-net sales accruals for other (chargebacks, distributor service fees, prompt pay discounts), sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.

[Table of Contents](#)

Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month periods ended March 31, 2024 and 2023, were as follows:

(\$'s in thousands)	Returns	Coupons	Managed Care Rebates	Other	Total
<b>Balance as of December 31, 2023</b>	<b>\$ 4,077</b>	<b>\$ 3,444</b>	<b>\$ 5,210</b>	<b>\$ 1,386</b>	<b>\$ 14,117</b>
Current provision related to sales in the current period	128	18,742	4,721	1,981	25,572
Payments/adjustments	(1,399)	(19,429)	(6,486)	(2,429)	(29,743)
<b>Balance as of March 31, 2024</b>	<b><u>\$ 2,806</u></b>	<b><u>\$ 2,757</u></b>	<b><u>\$ 3,445</u></b>	<b><u>\$ 938</u></b>	<b><u>\$ 9,946</u></b>

(\$'s in thousands)	Returns	Coupons	Managed Care Rebates	Other	Total
<b>Balance as of December 31, 2022</b>	<b>\$ 3,689</b>	<b>\$ 1,696</b>	<b>\$ 3,594</b>	<b>\$ 2,399</b>	<b>\$ 11,378</b>
Current provision related to sales in the current period	2,091	27,930	5,572	3,927	39,520
Payments/adjustments	(2,409)	(27,409)	(5,475)	(4,008)	(39,301)
<b>Balance as of March 31, 2023</b>	<b><u>\$ 3,371</u></b>	<b><u>\$ 2,217</u></b>	<b><u>\$ 3,691</u></b>	<b><u>\$ 2,318</u></b>	<b><u>\$ 11,597</u></b>

Gross-to-net sales accruals are primarily a function of product sales volume, mix of products sold, and contractual discounts or rebates. Our reserves for gross-to-net sales allowances were \$9.9 million at March 31, 2024, compared to \$11.6 million at March 31, 2023, a decrease of \$1.7 million. The decrease is largely driven by decreases in our reserves for government rebates. Since July 1, 2023, we no longer participate in the Medicaid Drug Rebate Program.

**Cost of Goods Sold**

Cost of goods sold increased by \$0.4 million, or 6%, to \$6.8 million for the three-month period ended March 31, 2024, from \$6.4 million for the three-month period ended March 31, 2023, due to the increase in net product revenue.

**Research and Development**

Research and Development expense increased by \$5.9 million, to \$7.9 million for the three-month period ended March 31, 2024, from \$2.0 million for the three-month period ended March 31, 2023. The increase is driven by the \$4.0 million filing fee payment to the FDA in January 2024 for DFD-29 and \$3.0 million expense for the contractual milestone payment owed to Dr. Reddy's Laboratories, Ltd ("DRL") triggered by the FDA's acceptance of our DFD-29 product NDA in March 2024. This was partially offset by lower clinical trial expenses to develop our DFD-29 product as the project concludes.

**Selling, General and Administrative**

Selling, general and administrative ("SG&A") expenses decreased by \$4.9 million, or 37%, to \$8.4 million for the three-month period ended March 31, 2024, from \$13.3 million for the three-month period ended March 31, 2023. The decrease is mainly due to our continued expense management efforts, primarily in sales and marketing and other SG&A areas, designed to improve operational efficiencies, optimize expenses and reduce overall costs.

**Interest Expense**

Interest expense decreased by \$0.1 million to \$0.5 million for the three-month period ended March 31, 2024, from \$0.6 million for the three-month period ended March 31, 2023. The decrease is primarily attributable to a lower principal balance outstanding during the three-months ended March 31, 2024 of \$15.0 million as compared to \$20.0 million during the three-months ended March 31, 2023.

**Liquidity and Capital Resources**

At March 31, 2024, we had \$24.1 million in cash and cash equivalents as compared to \$27.4 million of cash and cash equivalents at December 31, 2023.

[Table of Contents](#)

On December 27, 2023, we entered into a Credit Agreement (the "Credit Agreement") with SWK Funding LLC ("SWK"). The Credit Agreement provides for a term loan facility (the "Credit Facility") in the original principal amount of up to \$20.0 million. On the closing date, we drew \$15.0 million. The remaining \$5.0 million may be drawn at our request within 12 months after the closing date. Loans under the Credit Facility (the "Term Loans") mature on December 27, 2027, and bear interest at a rate per annum equal to the three-month term Secured Overnight Financing Rate ("SOFR") (subject to a SOFR floor of 5%) plus 7.75%. The interest rate resets quarterly. Interest payments began in February 2024 and are paid quarterly. Beginning in February 2026, we are required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans. The SWK Credit Facility also includes both revenue and liquidity covenants, restrictions as to payment of dividends, and is secured by substantially all assets of the Company. As of March 31, 2023, and as of the date of this Quarterly Report on Form 10-Q, the Company was in compliance with the financial covenants under the SWK Credit Facility.

On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333-269079), which was declared effective by the Securities and Exchange Commission ("SEC") on January 26, 2023. This shelf registration statement covers the offering, issuance and sale of up to an aggregate of \$150.0 million of our common stock, preferred stock, debt securities, warrants, and units (the "2022 Shelf"). In connection with the 2022 Shelf, we entered into an At Market Issuance Sales Agreement (the "Sales Agreement") relating to shares of our common stock. We may offer and sell up to 4,900,000 shares of its common stock, from time to time, under the Sales Agreement. During the three months ended March 31, 2024, we issued and sold 289,744 shares of common stock under the 2022 Shelf, generating net proceeds of \$1.5 million. At March 31, 2024, 3,861,553 shares remain available for issuance under the 2022 Shelf.

We regularly evaluate market conditions, our liquidity profile, and financing alternatives, including out-licensing arrangements for our products to enhance our capital structure. We may seek to raise capital through debt or equity financings to expand our product portfolio and for other strategic initiatives, which may include sales of securities under either the 2022 Shelf or a new registration statement or drawing on the SWK Credit Facility. We cannot make any assurances that such additional financing will be available and, if available, the terms may negatively impact the Company's business and operations. Our expectations are based on current assumptions, projected commercial sales of our products, clinical development plans and regulatory submission timelines, which may be uncertain and may not emerge as expected. Additionally, as a result of recurring losses, substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.

**Cash Flows for the Three-Month Periods Ended March 31, 2024 and 2023**

(\$'s in thousands)	Three-Month Periods Ended March 31,		Increase (Decrease)
	2024	2023	
Net cash used in operating activities	\$ (5,019)	\$ (956)	\$ (4,063)
Net cash provided by (used in) investing activities	—	(5,000)	5,000
Net cash provided by financing activities	1,637	52	1,585
<b>Net change in cash and cash equivalents</b>	<b>(3,382)</b>	<b>(5,904)</b>	<b>2,522</b>

*Operating Activities*

Net cash flows used in operating activities for the three-month period ended March 31, 2024 increased by \$4.1 million to \$5.0 million from net cash flows used by operating activities of \$1.0 million for the three-month period ended March 31, 2023. The increase was driven primarily by changes in net working capital primarily attributable to accounts receivable collections offset by vendor payables from our continued expense management efforts resulting in comparably lower vendor payables from the first quarter of 2023, and inventory, in addition to the net loss for the first quarter 2024.

*Investing Activities*

Net cash used in investing activities decreased by \$5.0 million from period to period. The three-month period ended March 31, 2023 reflects the \$5.0 million deferred cash payment paid in January 2023 related to the Vyne Product Acquisition.

*Financing Activities*

Net cash flows provided by financing activities for three-month period ended March 31, 2024 increased by \$1.6 million to \$1.6 million from \$0.1 million of cash flows provided by financing activities for the three-month period ended March 31, 2023. The increase is driven primarily by the net proceeds from issuances of common stock under our ATM.

*Material Cash Requirements*

In the normal course of business, we enter into contractual obligations that contain cash requirements of which the most significant currently include the following:

- We are required to make regular payments under the SWK Credit Facility. Based on the amount currently outstanding under the SWK facility and current interest rates, and assuming we do not make further draws under the SWK facility, we expect to make the following payments:

	Payments by Period				
	Total	Remainder of 2024	2025	2026	2027
Interest	\$ 6,273	\$ 1,501	\$ 1,993	\$ 1,693	\$ 1,086
Principal	15,000	—	—	4,500	10,500
Exit fee	750	—	—	—	750
Total	<u>\$ 22,023</u>	<u>\$ 1,501</u>	<u>\$ 1,993</u>	<u>\$ 6,193</u>	<u>\$ 12,336</u>

Should we elect to borrow the remaining \$5.0 undrawn balance under the SWB facility, we would expect to repay additional amounts each year until maturity.

- Pursuant to the Vyne Product Acquisition Agreement, upon the achievement of net sales milestones with respect to the products purchased in the Vyne Product Acquisition, we are also required to pay contingent consideration consisting of a one-time payment, per product, of \$10.0 million and \$20.0 million upon each product reaching annual net sales of \$100 million and \$200 million, respectively. Each required payment must only be paid one time following the first achievement of the applicable annual net sales milestone amount.
- On June 29, 2021, we entered into the DFD-29 Agreement to obtain the global rights for the development and commercialization of DFD-29 with DRL. Based on the development and commercialization of DFD-29, additional contingent regulatory and commercial milestone payments totaling up to \$155.0 million may also become payable. Royalties ranging from ten percent to twenty percent are payable on net sales of the product. In January 2024, the Company paid a \$4.0 million filing fee to the FDA upon filing of an NDA for DFD-29. The Company made a \$3.0 million contractual milestone payment to DRL in April 2024 based on the FDA's acceptance of our NDA for DFD-29 filed in January 2024.
- We are contractually obligated to make installment milestone payments of \$3.0 million on Ximino, all of which is classified as current.
- We are contractually obligated to make sales-based royalty payments to Dermira (for Qbrexza), Sun Pharmaceutical Industries (for Exelderm) and PuraCap Caribe (for Targadox). Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

**Item 4. Controls and Procedures**

*Evaluation of Disclosure Controls and Procedures*

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of March 31, 2024, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

*Changes in Internal Control over Financial Reporting*

No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations; which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.

**Part II. Other Information**

**Item 1. Legal Proceedings.**

To our knowledge, there are no legal proceedings pending against us, other than routine actions, administrative proceedings, and other actions not deemed material, that are expected to have a material adverse effect on our financial condition, results of operations, or cash flows. In the ordinary course of business, however, the Company may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company's product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages.

**Item 1A. Risk Factors.**

We have disclosed under the heading "Risk Factors" in the 2023 Form 10-K a number of risks which may materially affect our business, financial condition or results of operations. You should carefully consider these Risk Factors and other information set forth elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us may also materially adversely affect our business, financial condition and/or results of operations.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

During the period covered by this report, we have not sold any equity securities in transactions that were not registered under the Securities Act, and neither we nor our affiliates have purchased any equity securities issued by us.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not Applicable.

**Item 5. Other Information.**

None.

**Item 6. Exhibits**

<u>Exhibit No.</u>	<u>Description</u>
3.1	<a href="#">Third Amended and Restated Certificate of Incorporation of Journey Medical Corporation, filed as Exhibit 3.1 to Form 10-K, filed on March 28, 2022 and incorporated herein by reference.</a>
3.2	<a href="#">Amended and Restated Bylaws of Journey Medical Corporation, filed as Exhibit 3.2 to Form 10-K, filed on March 28, 2022 and incorporated herein by reference.</a>
4.1	<a href="#">Form of Common Stock Certificate, filed as Exhibit 4.1 to Form S-1, filed on October 22, 2021 and incorporated herein by reference.</a>
31.1	<a href="#">Certification of Chief Executive Officer of Journey Medical Corporation pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 14, 2024.**</a>
31.2	<a href="#">Certification of Principal Financial Officer of Journey Medical Corporation pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 14, 2024.**</a>
32.1	<a href="#">Certification of Chief Executive Officer of Journey Medical Corporation pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated May 14, 2024.***</a>
32.2	<a href="#">Certification of Principal Financial Officer of Journey Medical Corporation pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, dated May 14, 2024.***</a>
101	The following financial information from the Company's quarterly report on Form 10-Q for the period ended March 31, 2024, formatted in Inline Extensible Business Reporting Language (XBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statement of Stockholders' Equity, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements (filed herewith).**
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).**

\*\* Filed herewith.

\*\*\* Furnished herewith.

**SIGNATURES**

Pursuant to the requirements of the Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Journey Medical Corporation  
(Registrant)**

Date: May 14, 2024

By: /s/ Claude Maraoui

Claude Maraoui

President and Chief Executive Officer  
(Principal Executive Officer)

Date: May 14, 2024

By: /s/ Joseph Benesch

Joseph Benesch

Chief Financial Officer  
(Principal Financial Officer)

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER  
PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Claude Maraoui, certify that:

1. I have reviewed this report on Form 10-Q of Journey Medical Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Claude Maraoui

Claude Maraoui  
President and Chief Executive Officer  
(Principal Executive Officer)  
May 14, 2024

---

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO RULES 13A-14(A) AND 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Joseph Benesch certify that:

1. I have reviewed this report on Form 10-Q of Journey Medical Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15I and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principle;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Joseph Benesch  
Joseph Benesch  
Chief Financial Officer  
(Principal Financial Officer)  
May 14, 2024

---

---

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Claude Maraoui, President and Chief Executive Officer of Journey Medical Corporation (the "Company"), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company's quarterly report on Form 10-Q for the period ended March 31, 2024 (the "Report") filed with the Securities and Exchange Commission:

- Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

*/s/ Claude Maraoui*

Claude Maraoui  
President and Chief Executive Officer  
(Principal Executive Officer)  
May 14, 2024

---

---

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Joseph Benesch, Chief Financial Officer of Journey Medical Corporation (the "Company"), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company's quarterly report on Form 10-Q for the period ended March 31, 2024 (the "Report") filed with the Securities and Exchange Commission:

- Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Joseph Benesch  
Joseph Benesch  
Chief Financial Officer  
(Principal Financial Officer)  
May 14, 2024

---

---